Sartorius Stedim Bio

DIM
Real-time Euronext Paris - 09/19 05:35:06 pm
133.7EUR
+1.91%

The stock approaches again the support level

Envoyer par e-mail
Patrick Rejaunier
Equity Analyst

Strategy published on : 09/11/2019 | 03:57

long trade
Live

Entry price : 129.9€
Target : 145€
Stop-loss : 121.8€
Potential : 11.62%

Shares in Sartorius Stedim Biotech are retreating towards the lower bound of a horizontal trading range. Investors could use the proximity of this support area to initiate new long positions.
Investors have an opportunity to buy the stock and target the € 145.

Summary

● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.

● The company has solid fundamentals for a short-term investment strategy.


Strengths

● Graphically speaking, the timing seems perfect for purchasing the stock close to the EUR 122.3 support.

● Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 43% by 2021.

● The group's high margin levels account for strong profits.

● The company is in a robust financial situation considering its net cash and margin position.

● Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.

● For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.

● For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.

● The stock is in a well-established, long-term rising trend above the technical support level at 111.1 EUR


Weaknesses

● Based on current prices, the company has particularly high valuation levels.

● The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 47.69 times its estimated earnings per share for the ongoing year.

● The company is not the most generous with respect to shareholders' compensation.

● Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.

Zonebourse.com 2019
Envoyer par e-mail